Altalube

Mineral Oil And Petrolatum


Altaire Pharmaceuticals Inc.
Human Otc Drug
NDC 59390-198
Altalube also known as Mineral Oil And Petrolatum is a human otc drug labeled by 'Altaire Pharmaceuticals Inc.'. National Drug Code (NDC) number for Altalube is 59390-198. This drug is available in dosage form of Ointment. The names of the active, medicinal ingredients in Altalube drug includes Mineral Oil - 150 mg/g Petrolatum - 850 mg/g . The currest status of Altalube drug is Active.

Drug Information:

Drug NDC: 59390-198
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Altalube
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Mineral Oil And Petrolatum
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Altaire Pharmaceuticals Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Ointment
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:MINERAL OIL - 150 mg/g
PETROLATUM - 850 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Feb, 2002
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 15 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part349
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Altaire Pharmaceuticals Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:579996
1088146
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:T5L8T28FGP
4T6H12BN9U
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
59390-198-501 TUBE in 1 CARTON (59390-198-50) / 3.5 g in 1 TUBE01 Feb, 2002N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose eye lubricant

Product Elements:

Altalube mineral oil and petrolatum mineral oil mineral oil petrolatum petrolatum lanolin alcohols

Indications and Usage:

Uses • as a lubricant to prevent further irritation • to relieve dryness of the eye(s).

Warnings:

Warnings • for use in the eyes only. • save box for complete information. when using this product • avoid contamination, do not touch tip of container to any surface. • replace cap after each use. stop use and ask a doctor if • you experience eye pain, changes in vision, continued redness or irritation of the eye. • condition worsens or persists for more than 72 hours. keep this and all drugs out of the reach of children. if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product • avoid contamination, do not touch tip of container to any surface. • replace cap after each use.

Dosage and Administration:

Directions • pull down lower lid of the affected eye and apply a small amount (one-fourth inch) of ointment to the inside of the eyelid every 3-4 hours or as directed by a doctor.

Stop Use:

Stop use and ask a doctor if • you experience eye pain, changes in vision, continued redness or irritation of the eye. • condition worsens or persists for more than 72 hours.

Package Label Principal Display Panel:

Principal display panel actieyes altalube ointment white petrolatum and mineral oil lubricant eye ointment preservative free sterile net wt 3.5g (1/8 oz) actieyes altalube ointment white petrolatum and mineral oil lubricant eye ointment preservative free sterile net wt 3.5g (1/8 oz)

Further Questions:

Questions or comments? • (631) 722-5988 • 9am – 5 pm est monday- friday


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.